Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


G1 Therapeutics Inc.

Pausing the cell cycle to protect cancer patients' bone marrow

This article was originally published in Start Up

Executive Summary

Bone marrow suppression is arguably the worst side effect of chemotherapy, and to limit the damage chemotherapies do to healthy cells, clinicians now frequently follow protocols that call for supportive treatment with red blood cell stimulator EPO and/or GCSF. G1 Therapeutics Inc.’s drug candidate could one day displace growth factors by temporarily halting the growth of blood cells and their progenitors in the bone marrow so they can evade chemotherapies that target dividing cells.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts